Andrew Pannu

Founder & CEO

Andrew Pannu is the founder and CEO of Sleuth Insights, which he started in 2023 to give biopharma business development and strategy teams faster, better-sourced answers on assets, deals and competitors. Before Sleuth he worked in corporate development at Immunai and in business development at Covis Pharma, after starting his career at Deutsche Bank. He writes about the business side of biotech: dealmaking, valuations and commercial strategy. He holds a bachelor's degree in economics from UCLA.

LinkedIn ↗

X ↗

Resources

Industry Perspectives

The Biopharma Intelligence Gap

Intelligence Hub analysis

Andrew Pannu

Resources

What Compounding Intelligence Looks Like

Biopharma Data in an Age of AI

Where Top Pharma Is Focusing Its AI Efforts

The Last Mile from Output to Decision

WSJ: U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

Closing the Biopharma Intelligence Gap

The Biopharma Intelligence Gap

Intelligence Hub analysis

The Undruggable Cancer Targets Crossing Into the Clinic

2026 Pharma & Biotech IPOs by Month of Listing

Cardiometabolic RNA Competitive Map: 84 Programs, 9 Targets

In-Vivo CD19 Competitive Map: 91 Programs, 71 Developers

T15 Pharma Buyout Map: 29 Deals, ~$98B, and Who Has Room for More

Pharma I&I Has Evolved Into a Mechanism Stack

Eli Lilly’s 26 Deals in 2026: Breaking the LOE Cycle

1,838 ADCs: Topo-I and Tubulin Hold 86% of Named Payloads

TED and Graves’ Disease: Three Waves, One Autoimmune Root

Depression R&D Is a Barbell, Not a Crowd

China and the West Are Building Different Obesity Drugs

The ALS Development Field Is Trapped at Two Extremes

GLP-1 Whitespace: Sleep Apnea, PCOS and Diabetic Retinopathy

The China Biotech Partnership Funnel: 412 Assets to 12

Radioligand Therapy: Manufacturing Is the Primary Gate

Obesity Value Is Shifting From Efficacy to Access

Integrin α4β7 Landscape (2025): After Lilly’s Morphic Deal

In Vivo Cell Therapy Landscape After BMS–Orbital (Oct 2025)

Where Pharma Is Placing Early Oncology Bets (2025)

2025 Licensing Deal Trends by Therapeutic Area

Pharma Oncology (2025): Backbones, Modality-Agnostic Combos

Obesity Portfolio Gaps in Big Pharma (2025)

China Out-Licensing Deals YTD 2025 (July Update)

COPD Cytokine Chessboard After IL-33 Failures (2025)

OXR2 Narcolepsy Landscape After Takeda’s Phase 3 (2025)

RNAi Therapies Targeting Obesity (2025)

Big Pharma M&A and Licensing Deals in 2025

TL1A Global Competitive Landscape (2025)

Molecular Glue BD Landscape: $27B in Deals Since 2020

PD-1 RA Benchmarking After Rosnilimab Phase 2 (2025)

PD-L1 x VEGF Market Overview: Why Only Merck Moved (2025)

Why Biopharma Markets Converge on Duopolies

Eli Lilly’s Unique Position to Break the LOE Cycle (2025)

LOE Timing for Top Pharma Products by 2024 Sales (2025)

2024 FDA Novel Drug Approvals

Likely IRA Price Negotiation Picks for 2027 (Nov 2024)

Big Pharma Therapeutic M&A: 2019 to Present (2024)

Indication Selection Dictates Commercial Strategy

Radiopharmaceutical Portfolio Gaps in Big Pharma (2024)

Targeted Oncology: 425 Assets Across 19 Pharma (2024)

ADC M&A and IPO Activity: 2013 to Present (2024)

Grading Ten Single-Asset M&A Deals From 2016-2019

Gene Therapy Landscape: 42 Companies, 200+ Assets (2024)

Big Pharma Valuations Before and After Major LOEs (2024)

ADC Portfolio Gaps in Big Pharma (2024)

Pancreatic Cancer Treatment Landscape (2024)

Cell Therapy's Autoimmune Pivot (2024)

Five-Year Cancer Survival Rates Versus Incidence (2024)

A $50B CHIPS-Like Act for Drug Manufacturing? (2024)

Biotech Math (2024): Pharma’s $2.8B Blockbuster Hurdle

Cell Therapy Landscape: 45 Companies, 400+ Programs (2024)

CDK4/6 Competition in mER+ Breast Cancer (2024)

ADC Competitive Landscape: $125B+ in Deals Since 2019 (2023)

Sell-Side Drug Sales Forecasts Miss Widely (2013–2018)

How Pharma Has Capitalized on AI: Partnerships (2023)

How Pharma Is Replacing $200B+ in Upcoming LOEs (2023)

Neuropsychiatric Therapeutics: Competitive Landscape (2023)

Biotech Has a Consolidation Problem (2023)

Why Pharma Has Stayed Away From Cell Therapy M&A (2023)

How Merck Built a Blockbuster With Keytruda (2023)

Top-Selling Drugs for Medicare Price Negotiation (2023)

Big Pharma’s Top Products: Acquired vs. In-House (2023)

Obesity Drug On-Ramp Providers: Market Map (2023)

Obesity Competitive Landscape (Post-SELECT Update) (2023)

Neuro-Oncology Treatment Landscape (2023)

EGFRm+ NSCLC Treatment Landscape (2023)

Gene Editing Landscape: 42 Companies (2023)

Radiopharmaceuticals Market Map: 66 Companies (2023)

Asthma and COPD Competitive Landscape (2023)

Cell Therapy Supply Chain Market Map (2023)